Introduction to diabetes mellitus

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 1-11

  Kaul, Kirti ^a   Tarr, Joanna M ^a   Ahmad, Shamim I ^b   Kohner, Eva M ^a   Chibber, Rakesh ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALBIGLUTIDE; ALOGLIPTIN; BIGUANIDE DERIVATIVE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; OTELIXIZUMAB; RECOMBINANT HUMAN INSULIN; REMOGLIFLOZIN ETABONATE; RITUXIMAB; SAXAGLIPTIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG TARGETING; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PREGNANCY DIABETES MELLITUS; WEIGHT CONTROL;

EID: 84907846141     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_1     Document Type: Article

References (37)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes care 1998; 21(9):1414-1431.
2. WHO. 2011 [cited 2011; Available from: http://www.who.int/diabetes/en/.
3. Pessin JE, Saltiel AR. Signaling pathways in insulin action: moleculartargets of insulin resistance. J Clin Invest 2000; 106(2):165-169.
4. Phillips JM, Parish NM, Raine T et al. Type I diabetes development requires both CD4+ and CD8+ T-cells and can be reversed by non-depletin gantibodies targeting both T-Cell popul ations. Rev Diabet Stud 2009; 6(2):97-103.
5. Gorodezky C, Alaez C, Murguía A et al. HLA and autoimmune diseases: Type I diabetes (TID) as an example. Autoimmun Rev 2006; 5(3):87-94.
6. Jun S-K, Yoon Y-W. A new look at viruses in Type I diabetes. Diabetes/Metabolism Research and Reviews 2002; 19:8-31.
7. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21(4):518-524.
8. Masharani Ua KJH. Diabetes mellitus and hypoglycemia. Current Medical Diagnosis and Treatment, ed. Tierney Jr LM, McPhee SJ and Papadakis M. 2001, New York: McGraw-Hill.
9. Maria L, Rugolo SDS, Bentlin MR et al. Pre-eclampsia: Effect on the Fetus and Newborn. Neo Reviews 2011; 12:198-206.
10. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980.
11. WHO, WHOSG. Diabetes mellitus. Technical report Series 1985; Available from: http://whqlibdoc.who.int/trs/WHO-TRS-727.pdf.
12. Diagnosis and classification of diabetes mellitus. Diabetes care 2004; 27 Suppl 1:S5-S10.
13. Mehta SN, Wolfsdorf JI. Contemporary management of patients with type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39(3):573-593.
14. Zarogoulidis P, Papanas N, Kouliatsis G et al. Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv 2011; Epubahead of print.
15. Chaillous L, Lefevre H, Thivolet C et al. Oral insulin administration and residual (β- cell function inrecentonset type-I diabetes: multicentre randomised control trial. The Lancet 2000; 356(9229):545-549.
16. Card JW and Magnuson BA. A review of the efficacy and safety of Nanoparticle-Based Oral Insulin delivery system. Am Phys Soc 2011; Epub ahead of print.
17. Conditions, TNCCfC, Type 1 diabetes in adults: National clinical guideline for management in primary and secondary care. 2004, London: Royal college of physicians.
18. Conditions, TNCCfC, Type 2 diabetes: national clinical guideline for management in primary and secondary care. 2008, London: Royal college of physicians.
19. Nyenwe EA, Jerkins TW, Umpierrez GE et al. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2010; 60(1):1-23.
20. Gallwitz B. The evolving place of incretin-based ther apies intype 2 diabetes. Pediatr Nephrol 2010; 25(7):1207-1217.
21. Riedel MJ, Kieffer TJ. Treatment of diabetes with glucagon-like peptide-I gene therapy. Expert Opin Bioi Ther 2010; 10(12):1681-1692.
22. Washburn WN. Evolution of sodium glucose cotransporter 2 inhibitors as anti-diabeticagents. Expert Opin Ther Pat 2009; 19(11): 1485-1499.
23. Vardanyan M, Parkin E, Oruessner C et al. Pancreasvs islet transplantation: a call on the future. Curr Opin Organ Transplant 2010; 15(1): 124-130.
24. Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-re spon sive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26(4):443-452.
25. Oonez LJ, Knight KR. Cell therapy for diabetes: stem cells, progenitors or beta-cell replication? Mol Cell Endocrinol 2010; 323(1):55-61.
26. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007; 120(9 Suppl 2):S12-S17.
27. Ceriello A. Hyperglycaemia and the vessel wall: the pathophy siologic alaspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil 2010; 17 Suppl 1:S15-19.
28. Casellini CM, Vinik AI. Clinical manifestati ons and current treatment options for diabetic neuropathies. Endocr Pract 2007; 13(5):550-566.
29. Edwards JL, Vincent AM, Cheng HT et al. Diabetic neuropathy:mechanisms to management. Pharmacology & therapeutics. 2008; 120(1):1-34.
30. Selby JV, Fitz Simmons SC, Newman JM et al. The natural history and epidemiology of diabetic nephropathy. Implications for prevent ion and control. JAMA 1990; 263(14):1954-1960.
31. Lindley S, Dayan CM, Bishop A et al. Defective suppressor function in CD4+ CD25+ T-cells from patients with Type I Diabetes. Diabetes 2005; 54(1):92-99.
32. Salomon B, Lenschow DJ, Rhee L et al. B7/CD28 costimulationis essential for the homeostasis of the CD4+ CD25+ Immunoregulatory T-cells that control Autoimmune diabetes. Immunity 2000; 12(4):431-440.
33. Pozzilli P, Leslie RDO. Infections and diabetes: Mechanisms and prospects for prevention. Diabetic Medicine 2009; 11(10):935-941.
34. Vazquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin North Am 1995; 9(1):97-116.
35. Peleg AY, Weerarathna T, McCarthy JS et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes/Metabolism Research and Reviews 2006; 23(1):3-13.
36. Genco RJ, Grossi SG, Ho A et al. A proposed model linking inflamm ation to obesity, diabetes, and periodontal infections. J Periodont 2005; 76(11):2075-2084.
37. Eckhard M, Lengler A, Liersch J et al. Fungal foot infections in patients with diabetes mellitus-results of two independent investigations. Mycoses 2007; 50(S2): 14-19.